TG 1, interview with Piero Di Lorenzo TG 1 – 15th April

Comments (0) videos

[vc_row][vc_column][vc_video link=”https://youtu.be/SPAlgqo4n0s”][/vc_column][/vc_row][vc_row][vc_column][vc_text_separator title=”ENGLISH TRANSCRIPT” color=”sky”][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]

TG1 PRESENTER

We now have Piero Di Lorenzo on the line. He is the Managing Director of the company of Pomezia that developed the Coronavirus vaccine together with Oxford University. Good morning Mr. Di Lorenzo, what stage are we at with the trial?

PIERO DI LORENZO

Good morning. The pre-clinical phase has been completed, the results are quite good, in facts I’d say they are really good, so we have decided to proceed immediately with the human trial. To be specific, at the end of April, we will be sending off the first batch of vaccine that we have produced in the IRBM laboratories in Pomezia. In the meantime, the Jenner Institute in Oxford is selecting healthy volunteers to vaccinate, 550 in all. We think this vaccination process will begin by the end of May, early June, and we expect that as early as the end of September, there may be some convincing results. Assuming this all goes ahead as planned, we think the vaccine will be available by the end of the year. Bear in mind, just to be clear, that when we talk about the vaccine being available, we are not saying we are ready with a billion doses. We will start preparing the batches and get ready for mass vaccinations.

TG1 PRESENTER

OK, so the vaccine will be available by the end of the year and will then be distributed to the market. Thank you.

PIERO DI LORENZO

It will take time.

TG1 PRESENTER

OK, well thank you Mr. Di Lorenzo and keep up the good work.

[/vc_column_text][/vc_column][/vc_row]

Comments are closed.